Full-Time
Art Director
Eucalyptus
501-1,000 employees
Global telehealth platform offering digital clinics
No salary listed
New South Wales, Australia
In Person
Sydney-based; in-person collaboration and shoots required.
 Art, Graphics & Animation (2) |
|---|
| , |
- 4+ years of experience in advertising design, graphic design, art direction, or closely related creative roles. In-house experience
- Background in an Australian design or advertising agency, with a portfolio that demonstrates strong craft across ads, branding, and campaign identity
- A sharp visual eye with strengths in typography, layout, imagery, and building polished, premium brand expression
- Comfortable being hands-on in the work, using design craft to respond to briefs and turn ideas into high-quality creative outputs
- Sydney-based and able to work closely with the team in person, including regular involvement in shoots and collaborative creative development
- Empathetic & Culturally Aware: You understand that Juniper operates in a sensitive category. Your creative choices reflect empathy, credibility, and respect for the audience's journey
- Passionate About the Mission: You genuinely care about women's health and want to help build a brand that supports women through every stage of their journey
- Performance-Minded: You're comfortable working with performance data and using insights to improve your work. You understand that beautiful design should also drive results
- Create visually compelling advertising creative for Juniper across channels, with a strong focus on paid social and campaign work
- Lead the visual craft of projects from concept to execution, including art direction, storyboarding, campaign identity, and asset design
- Develop premium, on-brand visuals across a range of outputs such as ads, billboards, email creative, landing pages, and shoot concepts
- Work closely with copywriters, designers, and video editors to bring ideas to life from brief through to final delivery
- Contribute to the early creative process by generating design-led ideas and shaping how our brand shows up across growth marketing
Eucalyptus.vc runs digital healthcare clinics as a global telehealth service focused on patient-first care. Patients connect with certified practitioners for remote consultations, treatments, and ongoing care entirely through the online platform. The service provides end-to-end care in one digital ecosystem, from initial visit to follow-up, with revenue from fees for these clinical services. The company aims to make safe, effective care accessible worldwide by leveraging its global team of over 400 professionals to operate the clinics.
Company Size
501-1,000
Company Stage
Acquired
Total Funding
$1.3B
Headquarters
Sydney, Australia
Founded
2019
Simplify's Take
What believers are saying
- Hims & Hers $1.15B acquisition closes mid-2026, accessing U.S. market.
- Achieved triple-digit YoY revenue growth in 2025, $450M run-rate.
- Amigo AI partnership automates Juniper clinic workflows, cuts costs.
What critics are saying
- EU antitrust blocks Hims acquisition in 6-12 months over consolidation.
- Rebranding erodes 20-30% customer churn in Australia, UK within 12 months.
- GDPR fines halt Amigo AI in Germany, UK, costing €20M+ in 6 months.
What makes Eucalyptus unique
- Eucalyptus operates digital clinics in Australia, UK, Germany, Japan, Canada.
- Serves 775,000 customers with Juniper and Pilot consumer brands.
- Delivers behavioral health for weight management, diabetes, mental health.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Eucalyptus who can refer or advise you
Benefits
Employee Stock Purchase Plan
Flexible Work Hours
Hybrid Work Options
Wellness Program
Mental Health Support
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Stock Options
Company Equity
Conference Attendance Budget
Professional Development Budget
Birthdays?
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."
Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.
Hims & Hers stock rises after agreement to acquire Eucalyptus. ByInvesting.com Published 02/19/2026, 06:54 AM (C) Reuters. Investing.com - Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 7.8% Thursday morning after the company announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health leader with operations in Australia, the UK, Germany, Japan, and Canada. The acquisition, valued at up to $1.15 billion USD, will accelerate Hims & Hers' global expansion strategy while preserving its financial flexibility. The company will pay approximately $240 million in cash upon closing, with the remaining consideration structured as deferred payments over 18 months and additional earnout payments tied to financial targets through early 2029. Eucalyptus, which operates consumer brands including Juniper and Pilot, has served more than 775,000 customers and currently maintains an annual revenue run-rate exceeding $450 million USD. The company has demonstrated triple-digit YoY revenue growth in each quarter of calendar year 2025 while operating near profitability. "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare," said Andrew Dudum, founder and CEO of Hims & Hers. "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry." Following the acquisition's completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing the company's international business. Eucalyptus' portfolio of brands will transition into Hims & Hers over time. The transaction is expected to close during the middle of calendar year 2026, subject to regulatory approvals and other customary closing conditions. Hims & Hers plans to finance most of the acquisition using existing cash and future operating cash flows from its U.S. operations. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?
Amigo partners with Eucalyptus to scale ai-powered healthcare delivery across global telehealth network.
Lorikeet, an AI customer experience company, has secured an additional AUD 9 million in funding from Blackbird and existing investors, following a USD 5 million seed round last year. The funds will enhance Lorikeet's platform and expand its market presence in industries like healthcare and finance. Lorikeet's intelligent graph technology enables AI agents to handle complex support queries, improving customer satisfaction and support efficiency for clients like Eucalyptus and Magic Eden.